Lucid Diagnostics Inc expected to post a loss of 16 cents a share - Earnings Preview

Lucid Diagnostics

12/05/2025 14:21

Lucid Diagnostics Inc LUCD.OQ LUCD.O is expected to show a rise in quarterly revenue when it reports  results on May 14 for the period ending March 31 2025

The New York City-based  company is expected to report a 28.2% increase in revenue to $1.283 million from $1 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Lucid Diagnostics Inc is for a loss of 16 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Lucid Diagnostics Inc is $3.00​, above​ its last closing price of $1.13. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.19
-0.18
Beat
5.3
Sep. 30 2024
-0.22
-0.22
-0.25
Missed
-13.6
Jun. 30 2024
-0.22
-0.22
-0.23
Missed
-4.5​
Mar. 31 2024
-0.26
-0.27
-0.40
Missed
-49.3
​​Dec. 31 2023
-0.27
-0.26
-0.25
Beat
3
Sep. 30 2023
-0.27
-0.27
-0.34
Missed
-24.8​
Jun. 30 2023
-0.32
-0.32
-0.23
Beat
28.3
Mar. 31 2023
-0.34
-0.35
-0.40
Missed
-14.7

This summary was machine generated May 12 at 13:21 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)